Clinical trials: Cholera Vaccination
Cholera Vaccination
Trial to Evaluate Immunogenicity Non-Inferiority, Safety and Lot-to-Lot Consistency of Biovac OCV-S to Euvichol®-Plus
This Phase I/III clinical trial is intended to establish the immunogenicity and safety profile of Biovac OCV-S compared to available WHO pre-qualified vaccine Euvichol®-Plus in healthy adults and children and in adult people…
- Trial name
- NCT07304284
- Testing
- Experimental: Biovac OCV-S (inactivated whole-cell monovalent (O1) oral cholera vaccine), Active Comparator, Euvichol®-Plus
- Where
- 5 sites in South Africa
- Volunteers
- 2,824 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Cholera
Impact Study of Cholera Vaccination in Endemic Areas - Seroprevalence
This project aims to fill this essential knowledge gap by assessing the impact of oral cholera vaccine mass campaigns in 2 sites (urban and rural) in DRC, described in this protocol.
- Trial name
- NCT05829772
- Where
- 2 sites in Democratic Republic of the Congo
- Volunteers
- 7,000 people, healthy volunteers welcome
- Sponsor
- Epicentre
Typhoid and/or Cholera Vaccination
CVD 38000: Study of Responses to Vaccination With Typhoid and/or Cholera
This is an open-label, non-randomized study. The purpose of this study is to better understand how vaccines against typhoid fever and cholera affect the normal immune system and bacteria in the intestine.
- Trial name
- NCT03705585
- Testing
- Vivotif Typhoid Oral Vaccine, Vaxchora
- Where
- United States
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Cholera
Oral Cholera Vaccine Delivery in Rural Bangladesh
Background: Vibrio cholerae is one of the major causes of severe diarrheal disease in Bangladesh. It is estimated that there are about 450,000 cholera cases each year in Bangladesh.
- Trial name
- ROCV (NCT01811771)
- Testing
- Shanchol vaccine
- Where
- Bangladesh
- Volunteers
- 60,000 people, healthy volunteers welcome
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
Cholera Vaccination Reaction
Dose Escalation Study to Evaluate the Safety and Immunogenicity of the Cholera Conjugate Vaccine in Healthy Adults
This Phase I, first-in-human study is intended to primarily determine the safety of the dose range with or without Aluminum phosphate adjuvant expected to be needed for later clinical studies, to determine the nature of adverse…
- Trial name
- NCT05559983
- Testing
- OSP:rTTHc Cholera Conjugate Vaccine Cohort A, OSP:rTTHc Cholera Conjugate Vaccine with Aluminum phosphate adjuvant Cohort A, OSP:rTTHc Cholera Conjugate Vaccine Cohort B
- Where
- 3 sites in South Korea
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute